Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.51 +0.28 (+1.16%)
Official Closing Price Updated: 4:10 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Invo Fertility Stock Is Plunging After White House Announcement
INVO Fertility Inc (NASDAQ:IVF) shares are trading lower on Thursday as investors book profits following White House announcements aimed at making fertility treatments more affordable and accessible. 
Via Benzinga
Why Eli Lilly (LLY) Stock Is Down Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.5% in the afternoon session after political comments introduced significant uncertainty regarding the future pricing of the company’s... 
Via StockStory
Topics Economy Government
UK Health Agency Recommends GSK-Backed ViiV Healthcare's Apretude As Injectable HIV Treatment
NICE recommends ViiV Healthcare's Apretude as the first injectable PrEP for HIV prevention, offering an alternative to daily oral medication. 
Via Benzinga
QSM Asset Management Dumps 36,000 Whirlpool (WHR) Shares in Q3 2025
Via The Motley Fool
Topics Regulatory Compliance
Pfizer CEO Urges US-China Collaboration In Pharma; Stock Drops For 7th Day As Traders Hold For Dividend Payout
Via Stocktwits
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?
Trump's promise to cut cost of Novo Nordisk A/S drug Ozempic from $1,300 to $150 shakes GLP-1 gold rush, with potential impact on Eli Lilly and Pfizer. 
Via Benzinga
Topics Government
Eli Lilly Makes A Bold Claim For Its Biggest Cancer Drug
Eli Lilly said Friday a combo using Verzenio cut the risk of death by nearly 16% over two years for breast cancer patients. 
Via Investor's Business Daily
ASSET PLANNING Exits Full Stake in Pfizer Worth $2.7 Million
Via The Motley Fool
Topics Regulatory Compliance
AI: The Medical Maverick – Navigating Hype and Hope in Healthcare’s Digital Revolution
Artificial intelligence (AI) stands at the precipice of a profound transformation in healthcare, promising a future where diagnostics are sharper, treatments are more personalized, and patient care is... 
Via TokenRing AI
Topics Artificial Intelligence
Navigating the Currents: Volatility and Growth Define U.S. Markets Amidst AI Boom and Geopolitical Headwinds
As of October 16, 2025, the U.S. stock market is a tapestry woven with threads of robust corporate earnings, groundbreaking technological advancements, and persistent geopolitical and economic... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
QSM Asset Management Takes $11.5 Million Stake in Rio Tinto, Expands Energy Exposure
Via The Motley Fool
QSM Asset Management Buys $6.8 Million of Pfizer Stock as Pharma Giant Lags Market
Via The Motley Fool
A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years
It's the best time in a while to scoop up shares of this stock from the discount bin. 
Via The Motley Fool
Topics Intellectual Property World Trade
Why Moderna Might Be a One-Hit Wonder
Moderna's sales have plummeted in recent years along with diminishing demand for COVID vaccines. 
Via The Motley Fool
Dividend Duo Delights Investors: Meta Platforms and Johnson & Johnson Shine in 2025
In a year marked by evolving market dynamics and a persistent search for both growth and stability, two distinct titans of industry—Meta Platforms (NASDAQ: META) and Johnson & Johnson (NYSE: JNJ)—have... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Curious about the most active S&P500 stocks in today's session?
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Wednesday and uncover the stocks that are leading the way in terms of trading volume and market... 
Via Chartmill
Wall Street's Earnings Momentum Fades, Market Dips Amidst Trade Tensions
Wall Street witnessed a significant shift this Wednesday as an eagerly anticipated earnings push ultimately petered out, sending stocks into the red. This downturn followed a volatile Tuesday, which... 
Via MarketMinute
Topics Economy Supply Chain World Trade
Pfizer CEO Reportedly Says Vaccine Approvals Getting Harder
According to a report from Bloomberg, Bourla said that it's harder to get vaccine approvals and not drug approvals. 
Via Stocktwits
Topics Government World Trade
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields
 
Via Benzinga
1 Safe-and-Steady Stock Worth Your Attention and 2 We Question
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
AI Revolutionizes Quality Control: A New Era of Precision and Speed in Manufacturing, Electronics, and Pharmaceuticals
A groundbreaking wave of Artificial Intelligence (AI) tools is poised to fundamentally transform materials quality checking, ushering in an era of unparalleled precision, speed, and cost-efficiency... 
Via MarketMinute
Topics Artificial Intelligence Economy Fraud
Government Shutdown Casts Long Shadow Over Economy and Interest Rate Outlook Ahead of Powell's Pivotal Speech
The United States government is currently in the throes of its third week of a shutdown, a fiscal impasse that commenced on October 1, 2025, following a congressional failure to enact appropriations... 
Via MarketMinute
Topics Economy Government Regulatory Compliance
These S&P500 stocks are the most active in today's session
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Tuesday. Discover the stocks that are generating the highest... 
Via Chartmill
Pfizer Seeks Expanded Use Approval For Breast Cancer Drug
Pfizer's Tukysa improved progression-free survival in first-line HER2+ metastatic breast cancer, showing strong efficacy and a manageable safety profile. 
Via Benzinga
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential
Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least $5 billion. 
Via Benzinga
TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial
From Pfizer Inc.
Via Business Wire
David Gardner: 9 Foolish Truths I Hold to Be Self-Evident
Whether you're well steeped in Foolishness or at the beginning stages of your investing journey, these are nine foundational truths not to be forgotten. 
Via The Motley Fool
1 Profitable Stock for Long-Term Investors and 2 Facing Headwinds
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
Why BrightSpring Health Services (BTSG) Stock Is Trading Up Today
Shares of healthcare services provider BrightSpring Health Services (NASDAQ:BTSG) jumped 3.3% in the afternoon session after several analysts signaled increased confidence in the company, with UBS... 
Via StockStory
Topics Government Initial Public Offering
What's going on in today's session: S&P500 most active stocks
Explore the S&P500 index on Monday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.